Why the study?
Does ADAM17 inhibition prevent Angiotensin II-induced cardiovascular remodeling and hypertension in mice?
Population
Vascular ADAM17-deficient mice, control mice, and C57Bl/6 mice
Comparison
Vascular ADAM17 deficiency or treatment with a… vs Control mice infused with Angiotensin II
Design
Preclinical
Follow-up
2 weeks
Authors
Loading...
ADAM17 inhibition may target AngII-driven remodeling independent of BP in mice; leaves open translation to human hypertension therapy.
Does ADAM17 inhibition prevent Angiotensin II-induced cardiovascular remodeling and hypertension in mice?
Vascular ADAM17 mediates Angiotensin II-induced cardiovascular remodeling independent of blood pressure, highlighting it as a potential therapeutic target for hypertensive complications.
Takayanagi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: